KDR and myxofibrosarcoma: Nevertheless, this result does not completely exclude the possibility of VEGF inhibitors as a therapeutic strategy in myxofibrosarcomas, although pazopanib, a multi-kinase inhibitor also curbing VEGF-VEGFR axis, only showed limited efficacy 52.